Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutation

BACKGROUND: This study was designed to investigate the difference between brain metastases (BM) and non-brain metastases (non-BM) treated by osimertinib in advanced patients with an acquired EGFR T790M mutation after obtaining first-generation EGFR-TKI resistance. METHODS: A total number of 135 firs...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Respir Res
Main Authors: Li, Changhui, Nie, Wei, Guo, Jingdong, Xiong, Anning, Zhong, Hua, Chu, Tianqing, Zhong, Runbo, Xu, Jianlin, Lu, Jun, Zheng, Xiaoxuan, Zhang, Bo, Shen, Yinchen, Pan, Feng, Han, Baohui, Zhang, Xueyan
Formato: Artigo
Idioma:Inglês
Publicado: BioMed Central 2021
Assuntos:
Research
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC8114713/
https://ncbi.nlm.nih.gov/pubmed/33975616
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12931-021-01741-9
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares